Nitroglycerin

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	C3H5N3O9
Molecular Weight	227.0865
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O

InChI

InChIKey=SNIOPGDIGTZGOP-UHFFFAOYSA-N

InChI=1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2

HIDE SMILES / InChI

Molecular Formula	C3H5N3O9
Molecular Weight	227.0865
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021134s004lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16103363 | https://www.ncbi.nlm.nih.gov/pubmed/22040938

Nitroglycerin was first invented in 1847 and has been used as an active ingredient in the manufacture of explosives, mostly dynamite. Nitroglycerin came into medical use in 1878 as as a potent vasodilator (dilation of the vascular system) to treat heart conditions, such as angina pectoris and chronic heart failure. Upon administration, nitroglycerin is converted to nitric oxide (NO) by mitochondrial aldehyde dehydrogenase. NO is a potent activator of guanylyl cyclase (GC) by heme-dependent mechanisms.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Soluble guanylate cyclase 22 Target ID: CHEMBL2111348 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021134s004lbl.pdf	Activator 1404

Conditions

Condition	Modality	Highest Phase	Product
Angina 15 Sources: https://www.drugs.com/monograph/nitroglycerin.html	Primary	Approved 8307	NITROSTAT Approved Use Acute relief of angina pectoris secondary to CAD; acute prophylactic management in situations likely to provoke angina attacks; and long-term prophylactic management of angina pectoris. Launch Date 9.4703039E11
Myocardial infarction 103 Sources: https://www.drugs.com/monograph/nitroglycerin.html	Primary	Approved 8307	NITROGLYCERIN Approved Use Management of patients with acute myocardial infarction (MI). Nitroglycerin is one of the principal initial therapies of MI. Launch Date 3.71174408E11
Hypertension 546 Sources: https://www.drugs.com/monograph/nitroglycerin.html	Primary	Approved 8307	NITROGLYCERIN Approved Use IV nitroglycerin is used to control BP in perioperative hypertension, especially hypertension associated with cardiovascular procedures; to control BP in patients with severe hypertension† or in hypertensive crises for the immediate reduction of BP in patients in whom such reduction is considered an emergency (hypertensive emergencies), especially those associated with coronary complications (e.g., coronary ischemia, acute coronary insufficiency, acute left ventricular failure, postoperative hypertension [especially following coronary bypass surgery]); and to produce controlled hypotension during surgical procedures. Launch Date 3.71174408E11
Heart failure 87 Sources: https://www.drugs.com/monograph/nitroglycerin.html	Primary	Approved 8307	NITROGLYCERIN Approved Use IV nitroglycerin has been used in the management of acutely decompensated (e.g., congestive) heart failure and other low cardiac-output states. Launch Date 3.71174408E11

C_max

Value	Dose	Co-administered	Analyte	Population
1.7 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208424s000lbl.pdf	800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered:		NITROGLYCERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
84 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/	13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered:		GLYCERYL 1,2-DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
12.3 pg × min/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208424s000lbl.pdf	800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered:		NITROGLYCERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3380 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/	13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered:		GLYCERYL 1,2-DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
40 min DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208424s000lbl.pdf	800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered:		NITROGLYCERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
50 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/	13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered:		GLYCERYL 1,2-DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
1 ug/kg/min multiple, intravenous (starting) Dose: 1 ug/kg/min Route: intravenous Route: multiple Dose: 1 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/9916961	pregnant, 26 years n = 16 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/9916961	Disc. AE: Hypotension... AEs leading to discontinuation/dose reduction: Hypotension (4 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/9916961
8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/9916961	pregnant, 26 years n = 1 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9916961	Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (severe, 1 patient) Vomiting (severe, 1 patient) Headache (severe, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/9916961
35 ug/kg/min single, intravenous Dose: 35 ug/kg/min Route: intravenous Route: single Dose: 35 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/18680075	unhealthy, 50 years (range: 19 ± 74 years) n = 105 Health Status: unhealthy Age Group: 50 years (range: 19 ± 74 years) Sex: M+F Population Size: 105 Sources: https://pubmed.ncbi.nlm.nih.gov/18680075	Disc. AE: Hemodynamic test abnormal... AEs leading to discontinuation/dose reduction: Hemodynamic test abnormal (8 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/18680075
0.6 mg/h 1 times / day multiple, transdermal Highest studied dose Dose: 0.6 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.6 mg/h, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26263283	unhealthy, 51.4 ±4.3 years n = 11 Health Status: unhealthy Condition: menopausal hot flashes Age Group: 51.4 ±4.3 years Sex: F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/26263283	Sources: https://pubmed.ncbi.nlm.nih.gov/26263283
2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/110268	unhealthy, 57 - 71 years n = 2 Health Status: unhealthy Age Group: 57 - 71 years Sex: M Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/110268	Disc. AE: Pruritic rash, Erythema edematous... AEs leading to discontinuation/dose reduction: Pruritic rash (2 patients) Erythema edematous (2 patients) Vesicular eruption (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/110268
40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021134s009lbl.pdf https://pubmed.ncbi.nlm.nih.gov/6771417	unhealthy, 80 years n = 1 Health Status: unhealthy Condition: angina pectoris Age Group: 80 years Sex: M Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021134s009lbl.pdf https://pubmed.ncbi.nlm.nih.gov/6771417	Other AEs: Methemoglobinemia... Other AEs: Methemoglobinemia (grade 5, 1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021134s009lbl.pdf https://pubmed.ncbi.nlm.nih.gov/6771417
0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf	unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf	Other AEs: Headache, Lightheadedness... Other AEs: Headache (63%) Lightheadedness (6%) Hypotension (4%) Syncope (4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf
1.5 mg 2 times / day multiple, rectal Dose: 1.5 mg, 2 times / day Route: rectal Route: multiple Dose: 1.5 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021359s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021359s000lbl.pdf	Disc. AE: Hypotension... AEs leading to discontinuation/dose reduction: Hypotension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021359s000lbl.pdf
5 ug/kg 1 times / day single, subcutaneous Dose: 5 ug/kg, 1 times / day Route: subcutaneous Route: single Dose: 5 ug/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32282432	unhealthy, pediatric n = 57 Health Status: unhealthy Age Group: pediatric Population Size: 57 Sources: https://pubmed.ncbi.nlm.nih.gov/32282432	Sources: https://pubmed.ncbi.nlm.nih.gov/32282432

AEs

AE	Significance	Dose	Population
Hypotension	4 patients Disc. AE	1 ug/kg/min multiple, intravenous (starting) Dose: 1 ug/kg/min Route: intravenous Route: multiple Dose: 1 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/9916961	pregnant, 26 years n = 16 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/9916961
Headache	severe, 1 patient Disc. AE	8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/9916961	pregnant, 26 years n = 1 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9916961
Nausea	severe, 1 patient Disc. AE	8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/9916961	pregnant, 26 years n = 1 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9916961
Vomiting	severe, 1 patient Disc. AE	8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/9916961	pregnant, 26 years n = 1 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9916961
Hemodynamic test abnormal	8 patients Disc. AE	35 ug/kg/min single, intravenous Dose: 35 ug/kg/min Route: intravenous Route: single Dose: 35 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/18680075	unhealthy, 50 years (range: 19 ± 74 years) n = 105 Health Status: unhealthy Age Group: 50 years (range: 19 ± 74 years) Sex: M+F Population Size: 105 Sources: https://pubmed.ncbi.nlm.nih.gov/18680075
Erythema edematous	2 patients Disc. AE	2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/110268	unhealthy, 57 - 71 years n = 2 Health Status: unhealthy Age Group: 57 - 71 years Sex: M Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/110268
Pruritic rash	2 patients Disc. AE	2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/110268	unhealthy, 57 - 71 years n = 2 Health Status: unhealthy Age Group: 57 - 71 years Sex: M Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/110268
Vesicular eruption	2 patients Disc. AE	2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/110268	unhealthy, 57 - 71 years n = 2 Health Status: unhealthy Age Group: 57 - 71 years Sex: M Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/110268
Methemoglobinemia	grade 5, 1 patient	40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021134s009lbl.pdf https://pubmed.ncbi.nlm.nih.gov/6771417	unhealthy, 80 years n = 1 Health Status: unhealthy Condition: angina pectoris Age Group: 80 years Sex: M Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021134s009lbl.pdf https://pubmed.ncbi.nlm.nih.gov/6771417
Hypotension	4%	0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf	unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf
Syncope	4%	0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf	unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf
Lightheadedness	6%	0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf	unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf
Headache	63%	0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf	unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf
Hypotension	Disc. AE	1.5 mg 2 times / day multiple, rectal Dose: 1.5 mg, 2 times / day Route: rectal Route: multiple Dose: 1.5 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021359s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021359s000lbl.pdf

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:28787	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28787
ChemicalBook	CB2145318	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2145318
ZINC	ZINC000008214625	http://zinc15.docking.org/substances/ZINC000008214625

PubMed

Title	Date	PubMed
Continuous high-dose intracoronary nitroglycerin infusion in refractory coronary vasospasm.	1999 Dec	10745478
Randomized, double-blind, placebo-controlled trial of diazepam, nitroglycerin, or both for treatment of patients with potential cocaine-associated acute coronary syndromes.	2000 Aug	10958127
Cardiopulmonary bypass exacerbates oxidative stress but does not increase proinflammatory cytokine release in patients with diabetes compared with patients without diabetes: regulatory effects of exogenous nitric oxide.	2000 Jul	10884648
Headache characteristics during the development of tolerance to nitrates: pathophysiological implications.	2000 Jun	11037739
Acute myocardial ischemia after administration of ondansetron hydrochloride.	2000 Mar	10719974
Hypotensive interaction of sildenafil and nicorandil in rats through the cGMP pathway but not by K(ATP) channel activation.	2000 Nov	11138733
[Reactivity of cerebral vessels in patients with circulatory encephalopathy, arterial hypertension and cerebral hypoperfusion risk].	2001	11338853
The effect of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure and platelet function in acute stroke.	2001	11306778
Topical diltiazem ointment in the treatment of chronic anal fissure.	2001 Apr	11298624
Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis.	2001 Apr	11256976
Improved analysis of brachial artery ultrasound using a novel edge-detection software system.	2001 Aug	11457812
[Aspirin and nitroglycerine: a good combination for gastric mucosa].	2001 Aug-Sep	11481071
Investigations into migraine pathogenesis: time course for effects of m-CPP, BW723C86 or glyceryl trinitrate on appearance of Fos-like immunoreactivity in rat trigeminal nucleus caudalis (TNC).	2001 Feb	11298663
Continued cigarette smoking after coronary artery bypass surgery reduces endothelium-dependent vasodilation in internal thoracic artery grafts.	2001 Feb	11256542
Insulin resistance adds to endothelial dysfunction in hypertensive patients and in normotensive offspring of subjects with essential hypertension.	2001 Feb	11240849
Acute myocardial infarction secondary to coronary vasospasm during withdrawal from industrial nitroglycerin exposure--a case report.	2001 Feb	11228088
Reduced venous responsiveness to endothelin-1 but not noradrenaline in hypertensive chronic renal failure.	2001 Feb	11158403
Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease?	2001 Feb 15	11182106
NO donors inhibit Leishmania infantum cysteine proteinase activity.	2001 Feb 9	11342060
YC-1 enhances the responsiveness of tolerant vascular smooth muscle to glyceryl trinitrate.	2001 Jan	11201500
Acute congestive heart failure associated with a limited form of systemic sclerosis and primary biliary cirrhosis.	2001 Jan	11201376
Migraine with aura after administration of sublingual nitroglycerin tablets.	2001 Jan	11168608
Impaired vasodilator response to organic nitrates in isolated basilar arteries.	2001 Jan	11156558
Effect of isosorbide dinitrate on nitric oxide synthase under hypoxia.	2001 Jan	11150917
Prehospital management of rapid atrial fibrillation: recommendations for treatment protocols.	2001 Jan	11146008
Effects of C-peptide on forearm blood flow and brachial artery dilatation in patients with type 1 diabetes mellitus.	2001 Jul	11472302
Different mechanisms of isoproterenol-induced and nitroglycerin-induced syncope during head-up tilt in patients with unexplained syncope: important role of epinephrine in nitroglycerin-induced syncope.	2001 Jul	11469429
Gender difference in age-related changes in vascular function.	2001 Jul	11454139
Potentiation of sildenafil-induced hypotension is minimal with nitrates generating a radical intermediate.	2001 Jul	11444498
Transoesophageal acoustic quantification for evaluation of cardiac function during laparoscopic surgery.	2001 Jul	11437761
Pseudonormal diastolic filling unmasked with glyceryl trinitrate in patients with type 2 diabetes with poor metabolic control.	2001 Jul	11423529
Reduction of organic nitrates catalysed by xanthine oxidoreductase under anaerobic conditions.	2001 Jul 2	11420146
The effect of nitric oxide donors and L-arginine on the gastric electrolyte barrier.	2001 Jun	11453101
Long-term outcome of patients with ergonovine induced coronary constriction not associated with ischemic electrocardiographic changes.	2001 Jun	11433805
Changes in endothelium-dependent vasodilatation and alpha-adrenergic responses in resistance vessels during the menstrual cycle in healthy women.	2001 Jun	11397846
Augmentation of nitric oxide to treat detrusor-external sphincter dyssynergia in spinal cord injury.	2001 Jun 16	11425438
Effect of acute blood pressure reduction on endothelial function in the brachial artery of patients with essential hypertension.	2001 Mar	11327628
Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache.	2001 Mar	11284996
The BB-paraoxonase genotype is associated with impaired brachial reactivity after acute hypertriglyceridemia in healthy subjects.	2001 Mar	11238489
Comparison of provocative tests for unexplained syncope: isoprenaline and glyceryl trinitrate for diagnosing vasovagal syncope.	2001 Mar	11237545
Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases.	2001 Mar	11179059
Urban-rural differences in the quality of care for medicare patients with acute myocardial infarction.	2001 Mar 12	11231708
Comparison of topically applied 0.2% glyceryl trinitrate ointment, incision and excision in the treatment of perianal thrombosis.	2001 May	11432512
Audit of topical glyceryl trinitrate for treatment of fissure-in-ano.	2001 May	11432146
Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris.	2001 May	11352080
Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failure.	2001 May	11336107
Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta.	2001 May 1	11331261
[Nitrate headache in blasting work].	2001 May 15	11395995
Heart preservation with celsior solution improved by the addition of nitroglycerine.	2001 May 27	11391222
Treatment of chronic anal fissure with topical glyceryl trinitrate: a double-blind, placebo-controlled trial.	2001 May-Jun	11400799

Patents

Sample Use Guides

In Vivo Use Guide

Nitroglycerin in 5% Dextrose Injection is intended for intravenous administration using sterile equipment. It should be administered only via an infusion pump that can maintain a constant infusion rate. For treatment of acute anginal attack, one tablet of Nitrostat should be dissolved under the tongue or in the buccal pouch at the first sign of an acute anginal attack. The dose may be repeated approximately every 5 minutes, until relief is obtained. If the pain persists after a total of 3 tablets in a 15-minute period, or the pain is different than is typically experienced, prompt medical attention is recommended. Nitrostat may be used prophylactically 5 to 10 minutes prior to engaging in activities which might precipitate an acute attack.

Route of Administration: Other

In Vitro Use Guide

Vasoactivity of nitroglycerin was measured using an ex vivo assay. Mice thoracic aortae were removed, cleaned, and cut into 3-mm rings. Rings were mounted on strain gauge transducers under 1 g of resting tension, and maintained at 37°C in Krebs solution, bubbled continuously with 20% O2/5% CO2/75% N2. Rings were allowed to equilibrate for 1 h before active tension was induced with prostaglandin F2α. Application of Nitroglycerine relieve the F2α-induced strain with IC50 of 10-7 M for wt mice, and 10-5 for mtALDH-/- mice.

Substance Class	Chemical Created by `admin` on `Fri Dec 16 16:35:17 UTC 2022` Edited by `admin` on `Fri Dec 16 16:35:17 UTC 2022`
Record UNII	G59M7S0WS3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Nitroglycerin

Systematic Name

English

NITRO-DUR

Brand Name

English

RECTIV

Brand Name

English

NITRO IV

Brand Name

English

GLYCERIN TRINITRATE

Systematic Name

English

NITROGLYCERIN TABLETS [JAN]

Common Name

English

DILUTED NITROGLYCERIN [USP-RS]

Common Name

English

NITROGLYCERIN [ORANGE BOOK]

Common Name

English

PROPANE-1,2,3-TRIYL TRINITRATE

Systematic Name

English

MINITRAN

Brand Name

English

GLONOINUM [HPUS]

Common Name

English

TRINITRIN

Common Name

English

NITROGLYCERIN [MI]

Common Name

English

NITORA

Common Name

English

NTG

Common Name

English

TRINITRINE

Common Name

English

NITROGLYCERIN [VANDF]

Common Name

English

NITROMIST

Brand Name

English

NITRONAL

Brand Name

English

NITROL

Brand Name

English

GONITRO

Common Name

English

GLONOINUM

Common Name

English

C01DA02

Code

English

NITROGLYCERIN [USP IMPURITY]

Common Name

English

NITROLINGUAL

Brand Name

English

TRIDIL

Brand Name

English

GLYCERYL TRINITRATE

Systematic Name

English

NITROSTAT

Brand Name

English

DILUTED NITROGLYCERIN [USP MONOGRAPH]

Common Name

English

GLYCERYL TRINITRATE [MART.]

Common Name

English

TRANSDERM-NITRO

Brand Name

English

TRINITROGLYCERIN

Systematic Name

English

NITRO-BID

Brand Name

English

1,2,3-PROPANETRIOL, TRINITRATE

Systematic Name

English

DILUTED NITROGLYCERIN

Common Name

English

GLYCEROL TRINITRATE

Systematic Name

English

Glyceryl trinitrate [WHO-DD]

Common Name

English

IMX-150

Common Name

English

NITROGLYCERIN [HSDB]

Common Name

English

GLYCERYL TRINITRATE SOLUTION [EP MONOGRAPH]

Common Name

English

1,2,3-PROPANETRIOL TRINITRATE

Systematic Name

English

Classification Tree Code System Code

WHO-VATC

QC05AE01